{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:52:33Z","timestamp":1770753153176,"version":"3.50.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scholarship of Queen\u2019s University Belfast and the China Scholarship Council"},{"name":"the Department for the Economy studentship of UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>High-grade serous ovarian cancers (HGSOCs) are challenging to treat and often resistant to therapy. Despite ongoing therapeutic progress, relapse and poor outcomes remain common among both newly diagnosed and recurrent cases. Systematic high-throughput screening of clinically approved compounds holds significant promise for uncovering novel therapeutic responses and developing new treatment strategies for this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A panel of drugs were screened for cytotoxicity in five HGSOC cell lines, with drug efficacy quantified using the drug sensitivity score (DSS). All pairwise combinations of 384 low-cytotoxic drugs were screened by grouping 10 compounds in each well. The potent 10-compound combinations were deconvoluted into 2-drug pairings for secondary screening and ranked by the Bliss independent model and the Loewe additive model. Promising drug responses were further characterised in 3D spheroid cultures and patient ascites-derived cells (PADCs). The mechanism of action of the drugs was investigated by Western blot analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The DSS profile of drug responses provided a more robust clustering of 5 HGSOC cell lines according to their chemosensitivity responses compared to gene expression analysis of chemoresistance markers. Furthermore, chemoresistant HGSOC cell lines exhibited limited efficacy to single-agent treatments and generally demonstrated resistance to most anti-cancer agents. However, combination screens identified several novel drug pairings that were cytotoxic to chemoresistant HGSOC cells. Drug combinations involving traditional anticancer agents showed superior synergy and toxicity in chemosensitive cell lines, while all cell lines demonstrated good sensitivity to PI3K and HMG-CoA reductase inhibitors at sub-maximal clinically relevant concentrations, with the greatest sensitivity observed in chemoresistant cells. The combination of PI3K and HMG-CoA reductase inhibition significantly reduced the viability and growth of HGSOC spheroids. PADCs exhibited intrinsic sensitivity to HMG-CoA inhibition, while the combination with PI3K inhibition facilitated further dose reductions. Mechanistic studies revealed that the HMG-CoA inhibitor increased phospho-Akt levels in chemoresistant cell lines, sensitising them to PI3K inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates the application of multiplex drug combination screening to identify effective synergistic therapies. Co-targeting PI3-kinase and HMG-CoA reductase could be repurposed as a potent combination to treat chemoresistant HGSOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-025-01828-7","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T14:49:30Z","timestamp":1762440570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unbiased combination screening on repurposed drugs reveals synergistic potential of copanlisib and cerivastatin against chemoresistant high-grade serous ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Yu","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Umbreen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pepperrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlam","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Furlong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"1828_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA: a cancer journal for clinicians. 2021;71(1):7\u201333.","DOI":"10.3322\/caac.21654"},{"issue":"1","key":"1828_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, K\u00f6bel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. JNCI: J Natl Cancer Inst. 2019;111(1):60\u20138.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"3","key":"1828_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv: Int J Pathol. 2012;460(3):237\u201349.","journal-title":"Virchows Archiv: Int J Pathol"},{"issue":"5","key":"1828_CR4","doi-asserted-by":"publisher","first-page":"R303","DOI":"10.1530\/ERC-17-0336","volume":"25","author":"B van Zyl","year":"2018","unstructured":"van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-related Cancer. 2018;25(5):R303\u201318.","journal-title":"Endocrine-related Cancer"},{"issue":"10271","key":"1828_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10271):281\u201392.","journal-title":"Lancet"},{"issue":"7","key":"1828_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Cheng S-C, Hendrickson AEW, Penson RT, Schumer ST, Doyle LA, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(7):957\u201368.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1828_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1828_CR8","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","volume":"15","author":"E Giudice","year":"2024","unstructured":"Giudice E, Huang T-T, Nair JR, Zurcher G, McCoy A, Nousome D, et al. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat Commun. 2024;15(1):2805.","journal-title":"Nat Commun"},{"issue":"2","key":"1828_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273\u201386.","journal-title":"Biostatistics"},{"issue":"12","key":"1828_CR10","doi-asserted-by":"publisher","first-page":"e0189233","DOI":"10.1371\/journal.pone.0189233","volume":"12","author":"A Couttenier","year":"2017","unstructured":"Couttenier A, Lacroix O, Vaes E, Cardwell CR, De Schutter H, Robert A. Statin use is associated with improved survival in ovarian cancer: a retrospective population-based study. PLoS ONE. 2017;12(12):e0189233.","journal-title":"PLoS ONE"},{"issue":"20","key":"1828_CR11","doi-asserted-by":"publisher","first-page":"7768","DOI":"10.3390\/ijms21207768","volume":"21","author":"M Nunes","year":"2020","unstructured":"Nunes M, Henriques Abreu M, Bartosch C, Ricardo S. Recycling the purpose of old drugs to treat ovarian cancer. Int J Mol Sci. 2020;21(20):7768.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1828_CR12","first-page":"e133247","volume":"5","author":"JR Brown","year":"2020","unstructured":"Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, et al. Phase II clinical trial of Metformin as a cancer stem cell\u2013targeting agent in ovarian cancer. JCI Insight. 2020;5(11):e133247.","journal-title":"JCI Insight"},{"key":"1828_CR13","doi-asserted-by":"crossref","unstructured":"Madariaga A, Marastoni S, Colombo I, Mandilaras V, Cabanero M, Bruce J, et al. Phase I\/II trial assessing hydroxychloroquine and Itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC)(HYDRA-01). American Soc Clin Oncol. 2020.38(15_suppl):6049.","DOI":"10.1200\/JCO.2020.38.15_suppl.6049"},{"issue":"1","key":"1828_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1535-7163.MCT-19-0052","volume":"19","author":"HA Kenny","year":"2020","unstructured":"Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, et al. Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis. Mol Cancer Ther. 2020;19(1):52\u201362.","journal-title":"Mol Cancer Ther"},{"key":"1828_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-2215-5-30","volume":"5","author":"R Mezencev","year":"2012","unstructured":"Mezencev R, Wang L, McDonald JF. Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening. J Ovarian Res. 2012;5:1\u201311.","journal-title":"J Ovarian Res"},{"issue":"7","key":"1828_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","volume":"21","author":"W Sun","year":"2016","unstructured":"Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discovery Today. 2016;21(7):1189\u201395.","journal-title":"Drug Discovery Today"},{"issue":"1","key":"1828_CR17","doi-asserted-by":"publisher","first-page":"11574","DOI":"10.1038\/s41598-020-68441-0","volume":"10","author":"E Folkesson","year":"2020","unstructured":"Folkesson E, Niederdorfer B, Nakstad VT, Thommesen L, Klinkenberg G, L\u00e6greid A, et al. High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids. Sci Rep. 2020;10(1):11574.","journal-title":"Sci Rep"},{"issue":"23","key":"1828_CR18","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-20-1439","volume":"80","author":"T-T Huang","year":"2020","unstructured":"Huang T-T, Brill E, Nair JR, Zhang X, Wilson KM, Chen L, et al. Targeting the PI3K\/mTOR pathway augments CHK1 Inhibitor\u2013Induced replication stress and antitumor activity in High-Grade serous ovarian cancer. Cancer Res. 2020;80(23):5380\u201392.","journal-title":"Cancer Res"},{"issue":"4","key":"1828_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.tranon.2018.06.002","volume":"11","author":"N Sima","year":"2018","unstructured":"Sima N, Sun W, Gorshkov K, Shen M, Huang W, Zhu W, et al. Small molecules identified from a quantitative drug combinational screen resensitize cisplatin\u2019s response in drug-resistant ovarian cancer cells. Translational Oncol. 2018;11(4):1053\u201364.","journal-title":"Translational Oncol"},{"issue":"12","key":"1828_CR20","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/cancers12123784","volume":"12","author":"AM Noonan","year":"2020","unstructured":"Noonan AM, Cousins A, Anderson D, Zeligs KP, Bunch K, Hernandez L, et al. Matrix drug screen identifies synergistic drug combinations to augment SMAC mimetic activity in ovarian cancer. Cancers. 2020;12(12):3784.","journal-title":"Cancers"},{"issue":"12","key":"1828_CR21","doi-asserted-by":"publisher","first-page":"e1009689","DOI":"10.1371\/journal.pcbi.1009689","volume":"17","author":"R Schmucker","year":"2021","unstructured":"Schmucker R, Farina G, Faeder J, Fr\u00f6hlich F, Saglam AS, Sandholm T. Combination treatment optimization using a pan-cancer pathway model. PLoS Comput Biol. 2021;17(12):e1009689.","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"1828_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/2472555220970917","volume":"26","author":"DA Close","year":"2021","unstructured":"Close DA, Kirkwood JM, Fecek RJ, Storkus WJ, Johnston PA. Unbiased High-Throughput drug combination pilot screening identifies synergistic drug combinations effective against Patient-Derived and drug-Resistant melanoma cell lines. SLAS Discovery. 2021;26(5):712\u201329.","journal-title":"SLAS Discovery"},{"issue":"1","key":"1828_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41597-019-0255-7","volume":"6","author":"\u00c5 Flobak","year":"2019","unstructured":"Flobak \u00c5, Niederdorfer B, Nakstad VT, Thommesen L, Klinkenberg G, L\u00e6greid A. A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines. Sci Data. 2019;6(1):237.","journal-title":"Sci Data"},{"key":"1828_CR24","doi-asserted-by":"crossref","unstructured":"Lewis C, McQuaid S, Clark P, Murray P, McGuigan T, Greene C, et al. The Northern Ireland biobank: a cancer focused repository of science. Open J Bioresources. 2018;5(0):9.","DOI":"10.5334\/ojb.47"},{"issue":"2","key":"1828_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"J-H Zhang","year":"1999","unstructured":"Zhang J-H, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. SLAS Discovery. 1999;4(2):67\u201373.","journal-title":"SLAS Discovery"},{"issue":"11","key":"1828_CR26","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar S, Ianevski A, Mpindi J-P, Bychkov D, Fiere C, Ianevski P, et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36(11):3602\u20134.","journal-title":"Bioinformatics"},{"issue":"1","key":"1828_CR27","doi-asserted-by":"publisher","first-page":"18514","DOI":"10.1038\/s41598-020-75453-3","volume":"10","author":"KM Lappin","year":"2020","unstructured":"Lappin KM, Davis L, Matchett KB, Ge Y, Mills KI, Blayney JK. A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. Sci Rep. 2020;10(1):18514.","journal-title":"Sci Rep"},{"issue":"18","key":"1828_CR28","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32(18):2866\u20138.","journal-title":"Bioinformatics"},{"issue":"24","key":"1828_CR29","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.3390\/cancers14246246","volume":"14","author":"KL Alatise","year":"2022","unstructured":"Alatise KL, Gardner S, Alexander-Bryant A. Mechanisms of drug resistance in ovarian cancer and associated gene targets. Cancers. 2022;14(24):6246.","journal-title":"Cancers"},{"issue":"3","key":"1828_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170(3):564\u201376. e16.","journal-title":"Cell"},{"issue":"3","key":"1828_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00357-022-09413-z","volume":"39","author":"MJ Warrens","year":"2022","unstructured":"Warrens MJ, Hoef Hvd. Understanding the adjusted Rand index and other partition comparison indices based on counting object pairs. J Classif. 2022;39(3):487\u2013509.","journal-title":"J Classif"},{"issue":"4","key":"1828_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.tips.2020.01.011","volume":"41","author":"CT Meyer","year":"2020","unstructured":"Meyer CT, Wooten DJ, Lopez CF, Quaranta V. Charting the fragmented landscape of drug synergy. Trends Pharmacol Sci. 2020;41(4):266\u201380.","journal-title":"Trends Pharmacol Sci"},{"issue":"15suppl","key":"1828_CR33","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1200\/jco.2009.27.15_suppl.2582","volume":"27","author":"P Mainwaring","year":"2009","unstructured":"Mainwaring P, Nguyen T, Price G, Venter D. Ixabepilone and lapatinib for HER2-positive advanced breast cancer: preclinical rationale and phase I trial. J Clin Oncol. 2009;27(15suppl):2582.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1828_CR34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/1535-7163.MCT-19-0466","volume":"19","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Machiels J-P, Salles G, Rottey S, Rule SA, Cunningham D, et al. On-target pharmacodynamic activity of the PI3K inhibitor Copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors. Mol Cancer Ther. 2020;19(2):468\u201378.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"1828_CR35","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","volume":"27","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of Copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Ann Oncol. 2016;27(10):1928\u201340.","journal-title":"Ann Oncol"},{"key":"1828_CR36","first-page":"0","volume-title":"Screening technologies","author":"F Sheinerman","year":"2022","unstructured":"Sheinerman F. In: Cavalla D, editor. Screening technologies. Drug Repurposing: The Royal Society of Chemistry; 2022. ch.6. pp.101\u201328."},{"key":"1828_CR37","first-page":"0","volume-title":"Introduction and historical overview of drug repurposing opportunities","author":"S Pushpakom","year":"2022","unstructured":"Pushpakom S. In: Cavalla D, editor. Introduction and historical overview of drug repurposing opportunities. Drug Repurposing: The Royal Society of Chemistry; 2022. ch. 1, pp.1\u20133."},{"key":"1828_CR38","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3389\/fphar.2019.01664","volume":"10","author":"C Verbaanderd","year":"2020","unstructured":"Verbaanderd C, Rooman I, Meheus L, Huys I. On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front Pharmacol. 2020;10:1664.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1828_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.tranon.2018.11.016","volume":"12","author":"K Gorshkov","year":"2019","unstructured":"Gorshkov K, Sima N, Sun W, Lu B, Huang W, Travers J, et al. Quantitative chemotherapeutic profiling of gynecologic cancer cell lines using approved drugs and bioactive compounds. Translational Oncol. 2019;12(3):441\u201352.","journal-title":"Translational Oncol"},{"key":"1828_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00952-5","volume":"13","author":"BM Barnes","year":"2021","unstructured":"Barnes BM, Nelson L, Tighe A, Burghel GJ, Lin I-H, Desai S, et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 2021;13:1\u201319.","journal-title":"Genome Med"},{"key":"1828_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10637-008-9206-4","volume":"27","author":"A Br\u00fcning","year":"2009","unstructured":"Br\u00fcning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, et al. Bortezomib treatment of ovarian cancer cells mediates Endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Investig New Drugs. 2009;27:543\u201351.","journal-title":"Investig New Drugs"},{"issue":"6","key":"1828_CR42","doi-asserted-by":"publisher","first-page":"e0158208","DOI":"10.1371\/journal.pone.0158208","volume":"11","author":"\u00d8 Helland","year":"2016","unstructured":"Helland \u00d8, Popa M, Bischof K, Gjertsen BT, McCormack E, Bj\u00f8rge L. The HDACi Panobinostat shows growth Inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLoS ONE. 2016;11(6):e0158208.","journal-title":"PLoS ONE"},{"key":"1828_CR43","doi-asserted-by":"crossref","unstructured":"Kunos C, Stefan T, Jacobberger JW. Cabazitaxel-Induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells. Front Oncol. 2013;3:226.","DOI":"10.3389\/fonc.2013.00226"},{"issue":"4","key":"1828_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, Xie H-J, Li Y-Y, Wang X, Liu X-X, Mai J. Molecular mechanisms of platinum\u2013based chemotherapy resistance in ovarian cancer. Oncol Rep. 2022;47(4):1\u201311.","journal-title":"Oncol Rep"},{"issue":"49","key":"1828_CR45","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.18632\/oncotarget.27827","volume":"11","author":"JE den Ouden","year":"2020","unstructured":"den Ouden JE, Zaman GJ, Dylus J, van Doornmalen AM, Mulder WR, Grobben Y, et al. Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant Ascites. Oncotarget. 2020;11(49):4570.","journal-title":"Oncotarget"},{"issue":"1","key":"1828_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66.","journal-title":"Mol Cancer"},{"issue":"2","key":"1828_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","volume":"163","author":"S Gaillard","year":"2021","unstructured":"Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, et al. Lurbinectedin versus pegylated liposomal doxorubicin or Topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021;163(2):237\u201345.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1828_CR48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1828_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","volume":"164","author":"N Colombo","year":"2022","unstructured":"Colombo N, Tomao F, Panici PB, Nicoletto MO, Tognon G, Bologna A, et al. Randomized phase II trial of weekly Paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol. 2022;164(3):505\u201313.","journal-title":"Gynecol Oncol"},{"key":"1828_CR50","doi-asserted-by":"publisher","first-page":"1258228","DOI":"10.3389\/fonc.2023.1258228","volume":"13","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Moore KN, Monk BJ, Herzog TJ, Annunziata CM, O\u2019Malley DM, et al. Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol. 2023;13:1258228.","journal-title":"Front Oncol"},{"issue":"9","key":"1828_CR51","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","volume":"69","author":"K-T Kuo","year":"2009","unstructured":"Kuo K-T, Guan B, Feng Y, Mao T-L, Chen X, Jinawath N, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009;69(9):4036\u201342.","journal-title":"Cancer Res"},{"issue":"16suppl","key":"1828_CR52","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.1200\/JCO.2023.41.16_suppl.7555","volume":"41","author":"MH Dreyling","year":"2023","unstructured":"Dreyling MH, Santoro A, Lepp\u00e4 S, Demeter J, Follows G, Lenz G, et al. Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor Copanlisib in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023;41(16suppl):7555.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1828_CR53","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1182\/bloodadvances.2024013236","volume":"8","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Wang H, Feng J, Kim TM, Tao R, Zhang H, et al. CHRONOS-4: phase 3 study of Copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Adv. 2024;8(18):4866\u201376.","journal-title":"Blood Adv"},{"issue":"14","key":"1828_CR54","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1200\/JCO.21.01648","volume":"40","author":"S Damodaran","year":"2022","unstructured":"Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, et al. Phase II study of Copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F. J Clin Oncol. 2022;40(14):1552\u201361.","journal-title":"J Clin Oncol"},{"key":"1828_CR55","doi-asserted-by":"crossref","unstructured":"Matulonis UA, Hirsch MS, Palescandolo E, Kim E, Liu JF, Van Hummelen P, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS ONE. 2011;6(9):e24433.","DOI":"10.1371\/journal.pone.0024433"},{"key":"1828_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","volume":"5","author":"K Nakayama","year":"2006","unstructured":"Nakayama K, Nakayama N, Kurman RJ, Cope LM, Pohl G, Samuels Y, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006;5:779\u201385.","journal-title":"Cancer Biol Ther"},{"issue":"7Supplement","key":"1828_CR57","doi-asserted-by":"publisher","first-page":"CT042","DOI":"10.1158\/1538-7445.AM2024-CT042","volume":"84","author":"TA Yap","year":"2024","unstructured":"Yap TA, Dumbrava EE, Ahnert JR, Tsimberidou AM, Hong D, Piha-Paul SA, et al. Abstract CT042: NCI10217: phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of Copanlisib (Copa) and Olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations. Cancer Res. 2024;84(7Supplement):CT042\u2013CT.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"1828_CR58","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2023-181067","volume":"142","author":"JL Crombie","year":"2023","unstructured":"Crombie JL, Kim AI, Bartlett NL, Redd RA, Patterson V, Carey C, et al. A phase I study of Copanlisib and venetoclax in patients with relapsed or refractory diffuse large B-Cell lymphoma. Blood. 2023;142(Supplement 1):1735.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1828_CR59","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1182\/blood-2022-160157","volume":"140","author":"G Shouse","year":"2022","unstructured":"Shouse G, Siddiqi T, Popplewell LL, Muir A, Melgar I, Orand K, et al. A phase I trial of PI3K\u03b1\u03b4 inhibitor Copanlisib in combination with nivolumab in patients with richter\u2019s transformation (RT) or transformed Non-Hodgkin lymphoma (tNHL). Blood. 2022;140(Supplement 1):6633\u20134.","journal-title":"Blood"},{"issue":"2","key":"1828_CR60","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ygyno.2017.05.009","volume":"146","author":"TJ Vogel","year":"2017","unstructured":"Vogel TJ, Goodman MT, Li AJ, Jeon CY. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecol Oncol. 2017;146(2):340\u20135.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1828_CR61","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/1055-9965.EPI-18-1194","volume":"28","author":"BN Harding","year":"2019","unstructured":"Harding BN, Delaney JA, Urban RR, Weiss NS. Use of Statin medications following diagnosis in relation to survival among women with ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(7):1127\u201333.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1828_CR62","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1038\/s41598-017-05595-4","volume":"7","author":"E de Wolf","year":"2017","unstructured":"de Wolf E, Abdullah MI, Jones SM, Menezes K, Moss DM, Drijfhout FP, et al. Dietary geranylgeraniol can limit the activity of Pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep. 2017;7(1):5410.","journal-title":"Sci Rep"},{"key":"1828_CR63","first-page":"2478","volume":"7 12","author":"HM Jones","year":"2017","unstructured":"Jones HM, Fang Z, Sun W, Clark LH, Stine J, Tran A-QM, et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. Am J Cancer Res. 2017;7 12:2478\u201390.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"1828_CR64","doi-asserted-by":"publisher","first-page":"e25770","DOI":"10.4161\/onci.25770","volume":"2","author":"C Riganti","year":"2013","unstructured":"Riganti C, Massaia M. Inhibition of the mevalonate pathway to override chemoresistance and promote the Immunogenic demise of cancer cells: killing two birds with one stone. Oncoimmunology. 2013;2(9):e25770.","journal-title":"Oncoimmunology"},{"issue":"8","key":"1828_CR65","doi-asserted-by":"publisher","first-page":"167458","DOI":"10.1016\/j.bbadis.2024.167458","volume":"1870","author":"C Kato","year":"2024","unstructured":"Kato C, Iizuka-Ohashi M, Honda M, Konishi E, Yokota I, Boku S, et al. Additional Statin treatment enhances the efficacy of HER2 Blockade and improves prognosis in Rac1-high\/HER2-positive breast cancer. Biochimica et biophysica acta (BBA) -. Mol Basis Disease. 2024;1870(8):167458.","journal-title":"Mol Basis Disease"},{"issue":"9","key":"1828_CR66","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/79510","volume":"6","author":"Y Kureishi","year":"2000","unstructured":"Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor Simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004\u201310.","journal-title":"Nat Med"},{"issue":"1","key":"1828_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0008-6363(02)00618-1","volume":"57","author":"A Skaletz-Rorowski","year":"2003","unstructured":"Skaletz-Rorowski A, Lutchman M, Kureishi Y, Lefer DJ, Faust JR, Walsh K. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt\/PKB translocation to membrane domains in endothelial cells. Cardiovascular Res. 2003;57(1):253\u201364.","journal-title":"Cardiovascular Res"},{"issue":"7","key":"1828_CR68","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/aps.2012.59","volume":"33","author":"Y Jin","year":"2012","unstructured":"Jin Y, Sui H-j, Dong Y, Ding Q, Qu W-h, Yu S-x, et al. Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regulating the Akt\/mTOR and Akt\/GSK-3\u03b2 signaling pathways. Acta Pharmacol Sin. 2012;33(7):861\u201372.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"1828_CR69","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1016\/j.biomaterials.2011.12.051","volume":"33","author":"S Yang","year":"2012","unstructured":"Yang S, Kim H-M. The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. Biomaterials. 2012;33(10):2902\u201315.","journal-title":"Biomaterials"},{"issue":"9","key":"1828_CR70","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s12276-023-01079-w","volume":"55","author":"M Xiao","year":"2023","unstructured":"Xiao M, Xu J, Wang W, Zhang B, Liu J, Li J, et al. Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp Mol Med. 2023;55(9):1982\u201395.","journal-title":"Exp Mol Med"},{"key":"1828_CR71","doi-asserted-by":"crossref","unstructured":"Kma DL, Baruah DTJ. The interplay of ROS and the PI3K\/Akt pathway in autophagy regulation. Biotechnol Appl Chem. 2021;69(1):248\u201364.","DOI":"10.1002\/bab.2104"},{"issue":"5","key":"1828_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/cvm-2-5-205","volume":"2","author":"CD Furberg","year":"2001","unstructured":"Furberg CD, Pitt B. Withdrawal of Cerivastatin from the world market. Trials. 2001;2(5):205.","journal-title":"Trials"},{"issue":"21","key":"1828_CR73","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","volume":"292","author":"BM Psaty","year":"2004","unstructured":"Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactionsuse of Cerivastatin and risk of rhabdomyolysis. JAMA. 2004;292(21):2622\u201331.","journal-title":"JAMA"},{"key":"1828_CR74","doi-asserted-by":"crossref","unstructured":"Adams SP, Tiellet N, Alaeiilkhchi N, Wright JM. Cerivastatin for lowering lipids. Cochrane Database Syst Rev. 2020;1(1):CD012501.","DOI":"10.1002\/14651858.CD012501.pub2"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01828-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01828-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:03:57Z","timestamp":1762445037000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01828-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01828-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that human research participants provided informed consent for publication of the images and tables.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}